In this state-of-the-art review, we explore the literature on the efficacy of SGLT-2 inhibitors in patients with type 2 diabetes and NASH, and present arguments for and against the use of SGLT-2 inhibitors in this patient population. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.